Company intelligence / Profile preview

Regener-Eyes

Tampa, Florida, United States

Ownership: Private
Development stage: Other

Overview

Regener-Eyes produces biologic (formerly amniotic fluid-derived) eye drops for dry eye, which are commercially available but unapproved by the FDA. There is no published clinical trial data supporting efficacy, and the company has faced FDA compliance and product quality concerns, including a 2024 warning letter and a recent voluntary recall closure after design improvements to address potential contamination.[1][2][3][4][6][8]

Therapeutic areas: Ophthalmology
Modalities: Biologic
Industry: Biotech

Drug pipeline

1 asset

Regener-Eyes Professional Strength

Unknown

Beyond the preview

Go deeper on Regener-Eyes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regener-Eyes.

Explore the full profile